NCT03879694 2026-02-06
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 1 Completed
Clinical Trials
25 trialsNCT03289741 2025-05-09
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT02457156 2025-03-13
PANasta
University of Liverpool
Phase 3 Completed
NCT02795858 2025-02-19
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04871204 2024-10-31
OTIS
Karolinska University Hospital
Phase 2 Completed
NCT02381249 2023-11-27
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
St. James's Hospital, Ireland
Phase NA Completed
NCT02385617 2023-11-27
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
St. James's Hospital, Ireland
Phase NA Completed
NCT06080204 2023-10-18
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Changhai Hospital
Phase NA Completed
NCT02333565 2023-05-25
CEVOREM
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT05682209 2023-01-18
The Effect of Octreotide on Wound Drainage After Mastectomy
University College Hospital, Ibadan
Phase 4 Completed
NCT03734627 2021-08-16
EndoGut
St. James's Hospital, Ireland
Completed
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT04129255 2020-09-10
CSMS99
National Cancer Institute, Naples
Phase 2 Completed
NCT00226967 2020-01-27
Stress, Diurnal Cortisol, and Breast Cancer Survival
Stanford University
Completed
NCT02021942 2018-02-05
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Phase 2 Completed
NCT00182754 2017-04-11
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00002779 2016-12-15
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00033605 2016-07-13
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01121939 2016-02-05
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00008073 2013-12-19
Octreotide and Doxorubicin in Treating Patients With Advanced Cancer
University of Pittsburgh
Phase 1 Completed
NCT00004895 2012-06-06
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Northwestern University
Phase 2 Completed
NCT00257426 2012-02-14
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00250796 2010-01-07
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
University of New Mexico
Phase 2 Completed
NCT00616408 2008-02-15
Prediction of Tumor Shrinkage in Acromegaly
Federico II University
Completed
NCT00386984 2006-10-12
Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
University Hospital Freiburg
Phase 3 Completed